Full-Time

Regional Regulatory Lead Manager

LCM

CSL

CSL

10,001+ employees

Develops and delivers biotherapies and vaccines

Compensation Overview

$129k - $153k/yr

+ Incentive compensation + Equity

King of Prussia, PA, USA + 1 more

More locations: Waltham, MA, USA

Hybrid

Three days onsite per week required; relocation and mobility assistance are not provided.

Bachelor's, Master's, MBA, PhD, MD, Doctor of Veterinary Medicine (DVM)

Category
Legal & Compliance (1)
Required Skills
Veeva
Pharmacology

Get referred to CSL

See people who can refer or advise you

Requirements
  • A bachelor's degree in Pharmacy, Biology, Chemistry, Pharmacology, Clinical Medicine, or a related life science field is required.
  • A minimum of 5 years of regulatory or submission experience in the biotechnology or pharmaceutical industry is required.
  • At least 3 years of experience working on developmental products is required.
  • Knowledge and understanding of pharmaceutical or biological product development and regulatory requirements for product development and approval in one or more key regions, including the European Union, United States, or Japan, is required.
  • Relevant experience working in a complex and matrix environment is required.
  • Candidates must demonstrate strategic thinking, prudent risk assessment, and the ability to develop bold, agile, innovative approaches to complex challenges.
  • Candidates must have effective verbal and written communication skills and the ability to work successfully across all levels of the organization.
  • Candidates must foster productive working relationships within research and development and commercial functions.
Responsibilities
  • Contribute to an innovative, scientifically sound, global, integrated regulatory vision and strategy for assigned products with a patient-centric focus.
  • Partner with the assigned product Global Regulatory Affairs Strategy Team Global Regulatory Lead and other regional, labeling, and Chemistry, Manufacturing, and Controls members to ensure a unified Global Regulatory Affairs voice and appropriate risk assessment and decision-making.
  • Maintain bidirectional communication with regional commercial operations and Global Regulatory Affairs.
  • Engage with the health authority in the assigned region, maintain productive relationships with health-authority contacts, and drive positive regulatory outcomes with the respective health authority in conjunction with the Global Regulatory Lead.
  • Contribute to product health-authority interactions with support from the Global Regulatory Lead or Regulatory Therapeutic Area Head.
  • Partner with Global Regulatory Affairs Strategy Team members to achieve regulatory deliverables, including leading assigned tasks, and execute decisions promptly.
  • Be accountable for the assigned product relationship with a health authority, ensuring alignment with the product Global Regulatory Lead and escalating to the Regulatory Therapeutic Area Head when needed.
  • Negotiate on behalf of CSL with a health authority when needed to achieve the desired regulatory outcome.
  • Develop regional knowledge of health-authority requirements, regulatory filing pathways and categories, processes, and ways of working.
  • Provide internal stakeholders with guidance and assessments on addressing project challenges, leveraging regulatory opportunities, and managing risk for developmental, new, and marketed products.
  • Support regional regulatory activities assigned by the product Global Regulatory Lead, including core document preparation, product filing preparation for investigational, new, and marketed products, and health-authority engagements.
  • Prepare Module 1 documentation required for submissions and support responses to health-authority comments with guidance from the Global Regulatory Lead.
  • Contribute to Global Regulatory Affairs Strategy Team activities, strategy development, document reviews, and competitive regulatory intelligence.
  • Execute regional regulatory activities on time and achieve positive regulatory outcomes.
  • Partner with the Global Regulatory Lead to develop internal communications and distribute Global Regulatory Affairs Strategy communications to regional commercial stakeholders.
  • Connect with and maintain relationships with Global Regulatory Affairs Strategy Team members, including regional Global Regulatory Affairs Strategy and Regulatory Chemistry, Manufacturing, and Controls groups.
  • Foster effective relationships across Global Regulatory Strategy.
  • Update and maintain applicable regulatory systems, such as Veeva, to ensure tracking and compliance deliverables.
  • Apply CSL leadership capabilities to the role.
Desired Qualifications
  • An advanced degree in a related field, such as a Master of Science, Doctor of Philosophy, Doctor of Medicine, Doctor of Veterinary Medicine, or Master of Business Administration, is preferred.
  • Experience working in Regulatory Affairs with agency-interaction responsibility involving at least one health authority is preferred.
  • Clinical or device foundation is preferred.

CSL is a global biotechnology company that develops and delivers biotherapies and influenza vaccines. It focuses on plasma-derived and recombinant therapies for rare and serious diseases and sells to healthcare providers, hospitals, and governments across the Americas, Asia Pacific, and Europe. Its product range includes treatments for rare diseases, influenza vaccines, and antivenoms, produced through its R&D, manufacturing, and distribution operations. CSL differentiates itself by offering the broadest portfolio of plasma-derived and recombinant therapies and by leveraging its global footprint and emphasis on diversity to reach diverse markets. The company’s main goal is to save lives and protect health by expanding access to high-quality therapies and vaccines worldwide.

Company Size

10,001+

Company Stage

IPO

Headquarters

Parkville, Australia

Founded

1916

Get referred to CSL

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • FY26 HEMGENIX sales rose 25%, validating CSL’s gene-therapy commercialization engine.
  • CSL completed $176 million in FY26 cost savings, ahead of plan.
  • VarmX’s September 2025 option deal adds a potential $2.1 billion anticoagulation franchise.

What critics are saying

  • FY26 revenue fell 1% and underlying NPATA fell 2% on plasma weakness.
  • China albumin sales dropped 17% in FY26 after government cost-containment measures.
  • Pentagon ended the U.S. flu vaccine mandate in 2026, pressuring Seqirus demand and execution.

What makes CSL unique

  • CSL spans plasma, gene therapy, and influenza vaccines, unlike single-platform biotech peers.
  • HEMGENIX remains the only approved hemophilia B gene therapy across the U.S. and Europe.
  • CSL’s global plasma collection and manufacturing network supports hard-to-replicate immunoglobulin and albumin supply.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Time Off

Paid Vacation

Paid Sick Leave

Paid Holidays

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

2%
Yahoo Finance
Aug 17th, 2026
CSL reports 2% drop in annual profit to $3.14B on weak plasma sales

Australian biopharmaceutical company CSL reported a 2% decline in annual profit on Tuesday, as its core plasma division experienced falling revenue. The company posted an underlying net profit after tax of $3.14 billion on a constant currency basis for the year ended 30 June, down from $3.22 billion the previous year. CSL is among the world's leading flu vaccine manufacturers. The results reflect challenges in the plasma business, which forms a significant part of the company's operations.

Yahoo Finance
May 2nd, 2026
CSL to split Seqirus vaccine unit as shares slide 50% amid restructure and cost cuts

CSL has announced a restructuring plan including the separation of its Seqirus influenza vaccine business into a standalone entity, alongside workforce reductions and plasma collection centre closures. Management cited prolonged margin pressures and operational challenges as drivers for the changes. The announcement follows a sharp share price decline, with CSL trading at A$124.84, down 27.4% year-to-date and 50.1% over the past year. Three-year and five-year returns show declines of 56.3% and 51.0% respectively. The restructuring aims to simplify operations and refocus capital on higher-returning areas. Separating Seqirus could provide clearer visibility into CSL's core plasma and specialty therapies businesses, whilst allowing independent capital allocation decisions. However, investors face execution risks typical of separations of this scale, including one-off charges and operational disruption.

Yahoo Finance
Apr 23rd, 2026
CSL shares hit 2017 low as Pentagon scraps flu vaccine mandate for military personnel

Australian biotech CSL extended losses on Thursday, falling to its lowest level since August 2017, after the US Pentagon scrapped its flu vaccine mandate for military personnel. The stock dropped as much as 0.8%, bringing yearly losses to over 25%. The policy reversal threatens demand from a key institutional buyer, compounding CSL's existing challenges. The company's Seqirus vaccines unit generated $2.17 billion in revenue in fiscal 2025, representing 14% of total revenue. CSL has faced sustained pressure from slowing demand for plasma-derived therapies, higher costs and multiple earnings downgrades. The stock plunged 39% last year, its biggest annual drop since 2002. Analysts cite concerns over falling US flu vaccination rates, weaker Seqirus earnings and delayed strategic plans.

USA Herald
Sep 16th, 2025
CSL to Acquire VarmX in $2.2B Biotech Breakthrough Deal - USA Herald

In a high-stakes move that could reshape emergency medicine, global biotech giant CSL has struck an exclusive option agreement to acquire VarmX, a Netherlands-based biotech, in a deal valued at up to $2.2 billion. The announcement, made Tuesday by EQT Life Sciences, which counts VarmX in its portfolio, underscores just how valuable the Dutch company’s CSL to acquire VarmX in a $2.2B deal, backing breakthrough bleeding drug VMX-C001 with full trial funding.

CSL
Sep 16th, 2025
CSL Limited Celebrates 25 Years on the ASX

Global biotechnology leader, CSL, celebrated the Company’s 25th Anniversary of listing on the Australian Securities Exchange (ASX), commemorating the occasion with a ceremonial bell ring at...